Study guide

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD

Key Takeaways Explain This Topic AI

ACOG and ASAM establish that maintenance MOUD (methadone or buprenorphine) is the standard of care for pregnant persons with OUD; medically supervised withdrawal is strictly advised against due to >70-90% relapse and fetal distress.

The landmark MOTHER trial demonstrated comparable maternal retention between methadone and buprenorphine, while buprenorphine-exposed neonates required 89% less morphine for NAS and had 58% shorter hospital stays.

Gestational pharmacokinetics (40-50% plasma volume expansion, 50% GFR increase, progesterone CYP3A4 induction) accelerate clearance, frequently requiring split dosing (BID) or dose escalation.

Contemporary data show buprenorphine/naloxone combination products have equivalent maternal/neonatal safety to mono-products due to negligible (<1-2%) sublingual naloxone absorption.

Initiating naltrexone during pregnancy is contraindicated due to risks of the mandatory 7-14 day opioid-free washout; pre-conception naltrexone may be maintained after careful shared decision-making.

Last updated: September 2026

Perinatal Opioid Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD

Perinatal Opioid Use Disorder (OUD) represents one of the most critical clinical intersections in addiction nursing and advanced practice obstetrics. For the Certified Addictions Registered Nurse - Advanced Practice (CARN-AP), clinical care must be anchored in evidence-based consensus guidelines, deep mastery of gestational pharmacokinetics, destigmatizing patient-centered communication, and rigorous harm reduction. The primary clinical imperative in perinatal OUD is stabilizing maternal neurochemistry to prevent repeated cycles of intoxication and withdrawal, thereby protecting both maternal well-being and the developing fetoplacental unit.

Consensus Clinical Guidelines: ACOG, ASAM, and the Standard of Care

The American College of Obstetricians and Gynecologists (ACOG) (Committee Opinion No. 711) and the American Society of Addiction Medicine (ASAM) National Practice Guideline establish an unequivocal clinical consensus: Medications for Opioid Use Disorder (MOUD) —specifically opioid agonist pharmacotherapy with methadone or partial agonist pharmacotherapy with buprenorphine —is the standard of care for pregnant persons with OUD. +-----------------------------------------------------------------------------------------+

  • | ACOG / ASAM PERINATAL OUD CONSENSUS |
  • +------------------------------------+----------------------------------------------------+
  • | Clinical Domain | Guideline Recommendation |
  • +------------------------------------+----------------------------------------------------+
  • | Standard of Care Pharmacotherapy | Maintenance MOUD with Methadone or Buprenorphine |
  • | Medically Supervised Withdrawal | Strictly Advised Against (Detoxification / Taper) |
  • | Induction Timing | Initiate as early in pregnancy as possible |
  • | Third-Trimester Management | Expect dose escalation or split dosing |
  • | Postpartum Continuation | Maintain therapeutic MOUD; prevent dose collapse |
  • +------------------------------------+----------------------------------------------------+

Maintenance agonist therapy accomplishes critical clinical objectives:

Eliminates illicit opioid exposure: Suppresses illicit drug hunger and compulsive drug-seeking behavior, shielding the patient and fetus from unpredictable street drug contaminants (e.g., illicitly manufactured synthetic fentanyl, xylazine, nitazenes).

Stabilizes maternal-fetal hemodynamics: Prevents the rapid swings between maternal intoxication and acute withdrawal that cause intermittent uteroplacental vasoconstriction and fetal hypoxia.

Optimizes perinatal healthcare engagement: Enhances compliance with comprehensive prenatal care, nutritional supplementation, infectious disease screening, and social support services.

Reduces maternal mortality: Significantly decreases the risk of fatal maternal overdose, which peaks in the vulnerable late postpartum period.

The Perils of Medically Supervised Withdrawal (Detoxification) in Pregnancy

A recurring pitfall on the CARN-AP examination is the misconception that "detoxification" or opioid tapering during pregnancy protects the fetus from chemical dependence. Both ACOG and ASAM explicitly counsel against medically supervised withdrawal (assisted detoxification) during pregnancy.

Critical Clinical Rule: Medically supervised withdrawal (detoxification) in pregnancy is associated with maternal relapse rates exceeding 70% to 90% , catastrophic fatal maternal overdose, severe fetal distress, and preterm labor. Maintenance MOUD is the only evidence-based standard.

Maternal and Fetal Risks of Acute Withdrawal

Loss of Opioid Tolerance and Fatal Overdose: Following acute detoxification, maternal opioid tolerance drops precipitous within days. When the patient experiences the almost inevitable relapse triggered by neurobiological craving and social stressors, resuming illicit opioids at pre-detoxification dosages frequently causes fatal respiratory arrest.

Fetal Autonomic Stress and Hypoxia: Maternal withdrawal triggers massive catecholamine surges (norepinephrine and epinephrine storm from the locus coeruleus), causing acute placental vasoconstriction, maternal hypertension, and severe fetal hypoxia.

Obstetric Emergencies: Fetal withdrawal manifested in utero increases myocardial oxygen demand, drives meconium passage into the amniotic fluid (leading to fatal meconium aspiration syndrome), precipitates placental abruption, induces spontaneous abortion in early pregnancy, and triggers uterine hypertonicity leading to precipitous preterm labor.

While supervised tapering in highly selected, exceptionally stable residential inpatient settings has been studied, long-term follow-up demonstrates that sustained post-delivery abstinence is rare. Thus, CARN-AP clinicians must educate patients, families, and interdisciplinary obstetric colleagues that maintenance pharmacotherapy is safe, protective, and non-negotiable.

The Landmark MOTHER Trial: Methadone vs. Buprenorphine

Until 2010, methadone monotherapy was the sole established gold standard for pregnant persons with OUD. The Maternal Opioid Treatment: Human Experimental Research (MOTHER) trial (Jones et al., New England Journal of Medicine , 2010) fundamentally revolutionized perinatal addiction practice.

Trial Design and Methodology

Design: Multi-center, randomized, double-blind, double-dummy, flexible-dosing clinical trial.

Population: 175 opioid-dependent pregnant women randomized to either methadone (titrated to maintenance doses up to 140 mg/day) or buprenorphine mono-product (titrated up to 32 mg/day sublingual).

Primary Outcomes: Evaluated both maternal treatment efficacy/retention and neonatal outcomes (specifically Neonatal Abstinence Syndrome [NAS] severity, total medication needed for treatment, and length of hospital stay).

Landmark Findings and Comparative Outcomes MOTHER TRIAL: NEONATAL OUTCOME COMPARISONS

  • Outcome Metric Buprenorphine vs. Methadone
  • --------------------------------------------------------------------------------
  • Total Morphine Dose for NAS Treatment: 89% REDUCTION with Buprenorphine
  • (Mean 1.1 mg vs. 10.4 mg; p < 0.0091)
  • --------------------------------------------------------------------------------
  • Neonatal Hospital Length of Stay: 58% REDUCTION with Buprenorphine
  • (Mean 10.0 days vs. 17.5 days; p < 0.0091)
  • --------------------------------------------------------------------------------
  • Duration of NAS Treatment: 43% REDUCTION with Buprenorphine
  • (Mean 4.1 days vs. 9.9 days; p < 0.003)
  • --------------------------------------------------------------------------------
  • Maternal Retention / Attrition: Methadone demonstrated lower attrition
  • during induction (33% drop-out in bup group
  • vs. 18% in methadone group during dose-finding)
  • Clinical Parameter Methadone Maintenance Buprenorphine Maintenance
  • Mechanism of Action Full mu-opioid receptor (MOR) agonist Partial mu-opioid agonist / Kappa antagonist

Maternal Treatment Retention Superior retention during initial induction and stabilization phase Higher attrition rate during initial outpatient dose-finding/induction phase

Neonatal Abstinence Severity Higher peak NAS scores; higher percentage requiring pharmacotherapy Significantly milder NAS course; 89% less morphine required

Duration of NAS Treatment Longer duration of treatment (mean ~9.9 days) Shorter duration of treatment ( 43% reduction , mean ~4.1 days)

Neonatal Hospital Stay Extended neonatal stay (mean ~17.5 days) Substantially shorter neonatal stay ( 58% reduction , mean ~10.0 days)

Clinical Practice Role Preferred for patients already stable on methadone, those with severe fentanyl tolerance, or those failing buprenorphine Preferred first-line agent when initiating MOUD during pregnancy due to superior neonatal outcomes

Clinical Interpretation for the CARN-AP

Both methadone and buprenorphine are first-line agents. If a pregnant patient is newly seeking treatment, buprenorphine is often favored because of substantially milder neonatal withdrawal and shorter infant hospitalization. However, methadone provides superior maternal retention , making it the agent of choice for patients who struggle with the partial agonist ceiling of buprenorphine, patients with heavy unremitting fentanyl use, or those with significant treatment instability.

Imperative Clinical Rule: If a patient becomes pregnant while already maintained and stable on methadone, do NOT transition them to buprenorphine . Switching from a full agonist to a partial agonist in pregnancy introduces an extreme risk of precipitated withdrawal and relapse. The patient should remain on their stable methadone regimen.

Gestational Pharmacokinetics and Dosing Alterations

Pregnancy triggers profound, dynamic anatomical and physiological adaptations that alter drug absorption, distribution, metabolism, and elimination. Understanding these gestational pharmacokinetic changes is essential for the CARN-AP to prevent subtherapeutic plasma concentrations, late-day withdrawal, and fetal distress. GESTATIONAL PHARMACOKINETIC DYNAMICS

  • 1. Plasma Volume Expansion (40-50%) ==> Increased Volume of Distribution (Vd)
  • 2. Glomerular Filtration Rate (+50%) ==> Accelerated Renal Drug Clearance
  • 3. CYP3A4 & CYP2B6 Hepatic Induction ==> Accelerated Hepatic Biotransformation
  • 4. Progesterone & Placental Hormones ==> Decreased Elimination Half-Life (t1/2)
  • ----------------------------------------
  • NET RESULT: Plummeting Trough Drug Levels
  • EMERGENCE OF THIRD-TRIMESTER WITHDRAWAL
  • The Three Key Physiological Mechanisms

Expanded Plasma Volume and Fluid Distribution: Maternal intravascular blood volume expands by 40% to 50% , accompanied by increases in total body water and extracellular fluid. This dramatically increases the volume of distribution ( V d V_d V d ​ ) for both methadone and buprenorphine, diluting plasma drug concentrations.

Augmented Renal Blood Flow and GFR: Renal plasma flow and glomerular filtration rate increase by approximately 50% beginning in early pregnancy and persisting through the third trimester, accelerating renal clearance of parent compounds and metabolites.

Hepatic Cytochrome P450 Enzyme Induction: High circulating levels of maternal progesterone, estrogen, and placental human chorionic somatomammotropin induce hepatic phase I microsomal enzymes—predominantly CYP3A4 , CYP2B6 , and CYP2D6 . In the second and third trimesters, methadone clearance increases by more than 50% to 100% , and its elimination half-life plummets from the non-pregnant baseline of 24-36 hours down to 12 to 24 hours .

Clinical Management: Split Dosing and Escalation

Because of accelerated clearance, pregnant patients maintained on once-daily methadone frequently experience trough-level opioid withdrawal in the late afternoon and evening (12 to 18 hours after their morning dose).

The Pitfall of Single-Dose Escalation: Simply increasing the single morning dose (e.g., from 80 mg to 120 mg once daily) often fails to resolve late-day withdrawal and risks excessive peak sedation ( C max ⁡ C_{\max} C m a x ​ ) 2 to 4 hours post-ingestion.

The Gold Standard: Split Dosing: Dividing the total daily methadone dose into twice-daily (split) dosing (e.g., 50 mg PO every 12 hours rather than 100 mg once daily) flattens peak-to-trough fluctuations, maintains stable continuous maternal-fetal blood levels, prevents late-day withdrawal, and prevents peak sedation.

Buprenorphine Adjustments: Buprenorphine clearance is similarly accelerated during the late second and third trimesters. Dividing the daily buprenorphine dose into BID or TID administration (e.g., 8 mg sublingually twice daily or 8 mg morning / 4 mg afternoon / 4 mg evening) frequently abolishes emerging craving and withdrawal.

Buprenorphine Formulation Selection: Mono-Product vs. Combination Product

Historically, clinical guidance recommended prescribing the buprenorphine mono-product (Subutex) exclusively during pregnancy. This historical caution stemmed from theoretical concerns that fetal exposure to naloxone might cause fetotoxicity, teratogenicity, or acute fetal withdrawal.

Contemporary Evidence and Guideline Updates

Sublingual Naloxone Bioavailability: Naloxone has an extremely low sublingual bioavailability ( <1% to 2% ). When taken properly via the sublingual route, maternal systemic naloxone concentrations are practically undetectable, resulting in virtually no transplacental transfer.

Observational Safety Cohorts: Large-scale prospective and retrospective international registry cohorts (including studies from the United States, Sweden, Finland, and Australia) evaluated thousands of pregnancies exposed to buprenorphine/naloxone combination (Suboxone) versus buprenorphine mono-product. These studies consistently demonstrated no differences in the incidence of congenital malformations, birth weight, gestational age at delivery, or NAS severity.

Updated ACOG / ASAM Recommendations: Current guidelines affirm that buprenorphine/naloxone combination products can be safely continued or initiated in pregnancy . The combination product provides crucial protection against intravenous diversion or misuse, particularly in outpatient settings where unobserved dosing is standard.

Extended-Release Naltrexone and Antagonist Therapy in Pregnancy

Opioid antagonist therapy with extended-release injectable naltrexone (Vivitrol) or daily oral naltrexone carries distinct clinical caveats during pregnancy.

Safety Profile and Reproductive Data

Human reproductive safety data for naltrexone in pregnancy remain exceptionally limited compared to decades of robust safety literature for methadone and buprenorphine. Animal reproduction studies have shown early fetal loss at supra-therapeutic doses.

Clinical Management Guidelines for Naltrexone

Continuation of Pre-Conception Naltrexone: If a patient achieves sustained OUD remission on extended-release naltrexone and discovers they are pregnant, naltrexone may be continued after an exhaustive, shared decision-making discussion weighing the unknown fetal risks against the substantial maternal risk of relapse upon discontinuation. This applies particularly to highly motivated patients who adamantly refuse agonist therapy.

Absolute Contraindication for New Induction in Pregnancy: Naltrexone must NEVER be newly initiated during pregnancy . Initiating naltrexone requires a complete 7 to 14-day mandatory opioid-free washout period to avoid precipitating acute antagonist withdrawal. Attempting this washout period during pregnancy imposes severe, prolonged maternal-fetal withdrawal, precipitating fetal distress, placental abruption, and preterm labor, and carries an unacceptably high risk of maternal relapse and fatal overdose.